4.4 Review

Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature

Journal

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.urolonc.2019.05.013

Keywords

Kidney neoplasms; Renal cell carcinoma; Small renal mass; Surgical pathology; Decision making; Active surveillance

Ask authors/readers for more resources

Introduction: Many patients with small renal masses (SRM) undergo surgical resection of benign and potentially indolent renal masses. We review the available literature to quantify the proportion of renal tumors that are low-risk based on clinical radiographic size, and quantify the number of low-risk masses surgically removed in the United States. Methods: We systematically reviewed the literature for studies including pathologic findings after excision of renal masses. Inclusion criteria required studies capture both benign and malignant histology at surgical pathology, tumor grade, and stratification by radiographic tumor size. We queried our institutional database using the same parameters. Meta-analysis results were applied to SEER incidence and management data for renal masses. Very-low-risk tumors were defined as benign or grade 1 cT1a, and low-risk tumors as benign, grade 1, or grade 2 cT1a. Results: A total of 733 titles were reviewed at title screening with 6 full text articles and our institutional database included for meta-analysis. Pooled estimates of benign, very-low-risk, and low-risk tumors were stratified by tumor size: <= 2 cm (25.5%, 40.1%, and 89.3%), 2 to 3 cm (21.2%, 34.1%, and 84.5%), 3 to 4 cm (16.1%, 26.6%, and 77.1%), 4 to 6 cm (11.9%, 23.8%, and 66.4%), and >6 cm (7.2%, 12.6%, and 50.3%). An estimated 3,300 benign, 5,400 very-low-risk, and 13,600 low-risk SRMs were resected in 2014 in the United States. Conclusion: A substantial portion of patients with SRM are undergoing surgical excision despite harboring tumors of low metastatic potential. The rate of high-grade histology increased with increasing clinical radiographic size, which can be used in counseling and decision- making regarding placement on active surveillance. The number of low-risk SRM removed annually in the United States increased from 8,500 in 2000 to 13,600 in 2014 with stabilization in recent years. (C) 2019 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Radiology, Nuclear Medicine & Medical Imaging

[18F]DCFPyL PET/CT for Imaging of Prostate Cancer

Steven P. Rowe, Andreas Buck, Ralph A. Bundschuh, Constantin Lapa, Sebastian E. Serfling, Thorsten Derlin, Takahiro Higuchi, Michael A. Gorin, Martin G. Pomper, Rudolf A. Werner

Summary: Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). [ (18) F]DCFPyL has been widely utilized for staging, restaging, and change in management, and has shown promise for response assessment in patients under specific treatments.

NUKLEARMEDIZIN-NUCLEAR MEDICINE (2022)

Article Oncology

Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions

Shaan Setia, Jamaal Jackson, Demetri Cendo, Michael A. Gorin, Matthew Allaway, Srinivas Vourganti

Summary: The study evaluated the diagnostic performance of systematic freehand transperineal biopsy (fTPb), finding that combining it with the Prostate Biopsy Collaborative Group (PBCG) nomogram can effectively predict clinically significant cancers. Patients with prostate cancer who underwent pre-biopsy multiparametric magnetic resonance imaging had an increased number of biopsy cores and a significantly higher detection rate of clinically significant cancer.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Biochemical Research Methods

High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL

Rudolf A. Werner, Bilel Habacha, Susanne Luetje, Lena Bundschuh, Takahiro Higuchi, Philipp Hartrampf, Sebastian E. Serfling, Thorsten Derlin, Constantin Lapa, Andreas K. Buck, Markus Essler, Kenneth J. Pienta, Mario A. Eisenberger, Mark C. Markowski, Laura Shinehouse, Rehab AbdAllah, Ali Salavati, Martin A. Lodge, Martin G. Pomper, Michael A. Gorin, Ralph A. Bundschuh, Steven P. Rowe

Summary: This study evaluated the test-retest repeatability of lesion uptake in patients imaged with F-18-DCFPyL PET/CT. The results showed that SUV parameters demonstrated high repeatability, especially in lymph nodes, while volumetric parameters showed low repeatability.

MOLECULAR IMAGING (2022)

Article Oncology

Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer

Andrew F. Voter, Rudolf A. Werner, Kenneth J. Pienta, Michael A. Gorin, Martin G. Pomper, Lilja B. Solnes, Steven P. Rowe

Summary: This article provides an overview of PSMA, F-18-DCFPyL, and compares their performance to conventional prostate imaging modalities. The clinical trials OSPREY and CONDOR have shown the superiority of F-18-DCFPyL in staging and restaging prostate cancer. The remarkable diagnostic accuracy of PSMA-PET is reshaping prostate cancer imaging.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Article Oncology

Robotic-assisted tumor enucleation versus standard margin partial nephrectomy: Perioperative, renal functional, and oncologic outcomes for low and intermediate complexity renal masses

Hiten D. Patel, Elizabeth L. Koehne, Keshava Gali, Nicholas J. Lanzotti, Goran Rac, Shalin Desai, Gaurav Pahouja, Marcus L. Quek, Gopal N. Gupta

Summary: This study compared the perioperative, functional, and oncologic outcomes of robotic-assisted tumor enucleation (TE) to standard margin partial nephrectomy (SPN). The results showed that TE had lower blood loss, shorter operative time, shorter length of stay, and fewer complications compared to SPN. TE also resulted in better preserved renal function in the first year, with a lower rate of stage >= 3 chronic kidney disease by 12 months. Although TE had higher positive margin rates, long-term recurrence rates were similar, suggesting that disruption of the tumor pseudocapsule during TE has limited impact on oncologic outcomes.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Oncology

Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage

Hiten D. Patel, Amy Man, Elizabeth L. Koehne, Goran Rac, Alessa P. Aragao, Robert C. Flanigan, Alex Gorbonos, Gopal N. Gupta, Michael E. Woods, Maria M. Picken, Marcus L. Quek

Summary: Sarcomatoid dedifferentiation in renal cell carcinoma is associated with worse overall survival and recurrence-free survival. The degree of sarcomatoid histology is positively correlated with survival outcomes.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Urology & Nephrology

A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators

Hiten D. Patel, Elizabeth L. Koehne, Steven M. Shea, Andrew M. Fang, Marielia Gerena, Alex Gorbonos, Marcus L. Quek, Robert C. Flanigan, Ari Goldberg, Soroush Rais-Bahrami, Gopal N. Gupta

Summary: A prostate cancer risk calculator incorporating multiparametric magnetic resonance imaging (mpMRI) has been developed and validated, outperforming other risk calculators in diagnosing high-risk prostate cancer and potentially reducing unnecessary biopsies.

BJU INTERNATIONAL (2023)

Article Oncology

Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions

Andrew M. Fang, Luke A. Shumaker, Kimberly D. Martin, Jamaal C. Jackson, Richard E. Fan, Ghazal Khajir, Hiten D. Patel, Nachiketh Soodana-Prakash, Srinivas Vourganti, Christopher P. Filson, Geoffrey A. Sonn, Preston C. Sprenkle, Gopal N. Gupta, Sanoj Punnen, Soroush Rais-Bahrami

Summary: Elevated PSA density, older age, and a biopsy-naive status are associated with clinically significant prostate cancer (CSPCa) in men with PI-RADS 3 lesions, while a prior negative biopsy is negatively associated. A predictive model can prevent unnecessary biopsies for PI-RADS 3 lesions while missing only a few cases of CSPCa.

CANCER (2022)

Article Oncology

MRI versus non-MRI diagnostic pathways before radical prostatectomy: Impact on nerve-sparing, positive surgical margins, and biochemical recurrence

Hiten D. Patel, Yudai Okabe, Goran Rac, Gaurav Pahouja, Shalin Desai, Steven M. Shea, Alex Gorbonos, Marcus L. Quek, Robert C. Flanigan, Ari Goldberg, Gopal N. Gupta

Summary: This study compared the impact of MRI vs. non-MRI diagnostic pathways on surgical outcomes for patients undergoing radical prostatectomy (RP). The results showed that MRI-based diagnostic approach was associated with lower positive surgical margin rates, higher utilization of bilateral nerve-sparing, and improved cancer control by biochemical recurrence.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Oncology

Disparities in access to robotic technology and perioperative outcomes among patients treated with radical prostatectomy

Charles D. Logan, Ashorne K. Mahenthiran, Mohammad R. Siddiqui, Dustin D. French, Matthew T. Hudnall, Hiten D. Patel, Adam B. Murphy, Joshua A. Halpern, David J. Bentrem

Summary: Most radical prostatectomies are done with robotic assistance. This study examined disparities in access and outcomes of robot-assisted radical prostatectomy (RARP) and found that non-Hispanic Black and Hispanic patients were less likely to receive RARP, and underinsured patients had lower rates of RARP. RARP was associated with decreased perioperative mortality and improved overall survival compared to open radical prostatectomy (ORP).

JOURNAL OF SURGICAL ONCOLOGY (2023)

Article Oncology

Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 2018

Anas Elgenidy, Ahmed K. Awad, Huzaifa Ahmad Cheema, Abia Shahid, Salah Eddine Oussama Kacimi, Mostafa G. Aly, Nirmish Singla, Ahmed M. Afifi, Hiten D. Patel

Summary: This study aimed to assess the frequency and risk of different causes of death in patients with renal cell carcinoma (RCC) in the United States. The majority of deaths were due to kidney cancer, but a significant proportion was caused by non-cancerous reasons. The proportion of deaths attributed to RCC decreased with increasing follow-up, and cardiovascular diseases and cerebrovascular diseases were the most common non-RCC-related causes of death. Coordination of multidisciplinary care is needed to prevent death from non-cancerous causes, depending on the stage of the disease.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2023)

Article Medicine, Research & Experimental

T cell metabolic reprogramming in acute kidney injury and protection by glutamine blockade

Kyungho Lee, Elizabeth A. Thompson, Sepideh Gharaie, Chirag H. Patel, Johanna T. Kurzhagen, Phillip M. Pierorazio, Lois J. Arend, Ajit G. Thomas, Sanjeev Noel, Barbara S. Slusher, Hamid Rabb

Summary: T cells in acute kidney injury (AKI) undergo metabolic reprogramming, and targeting the T cell glutamine pathway could be a promising therapeutic approach. Ischemic AKI in mice showed the presence of a distinct T cell subset with altered expression of certain metabolic proteins. Similarly, human nonischemic and ischemic kidney tissue exhibited similar findings. Inhibition of glutamine with JHU083 attenuated renal injury and reduced T cell activation and proliferation in AKI.

JCI INSIGHT (2023)

Article Urology & Nephrology

African American Men have Increased Risk of Prostate Cancer Detection Despite Similar Rates of Anterior Prostatic Lesions and PI-RADS Grade on Multiparametric Magnetic Resonance Imaging

Hiten D. Patel, Chirag P. Doshi, Elizabeth L. Koehne, Spencer Hart, Michelle Van Kuiken, Marcus L. Quek, Robert C. Flanigan, Gopal N. Gupta

Summary: The study aimed to compare the frequency of anterior prostate lesions on mpMRI between African American and non-African American men and evaluate the implications for prostate cancer detection. Results showed that men with APLs were twice as likely to have PCa or csPCa, but there was no significant difference in the proportion of APL PCa or csPCa between African American and non-African American men, indicating similar rates of APLs on mpMRI between the two groups.

UROLOGY (2022)

Review Urology & Nephrology

Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis

Spyridon P. Basourakos, Mark N. Alshak, Patrick J. Lewicki, Emily Cheng, Michael Tzeng, Antonio P. DeRosa, Mathew J. Allaway, Ashley E. Ross, Edward M. Schaeffer, Hiten D. Patel, Jim C. Hu, Michael A. Gorin

Summary: A systematic review and meta-analysis were conducted to evaluate infectious complications after transperineal prostate biopsy with or without the administration of prophylactic antibiotics. The study found that prophylactic antibiotics do not decrease the rate of postbiopsy sepsis but may have a small benefit in terms of preventing less serious infections.

EUROPEAN UROLOGY OPEN SCIENCE (2022)

Article Oncology

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma

Michael A. Gorin, Hiten D. Patel, Steven P. Rowe, Noah M. Hahn, Hans J. Hammers, Alice Pons, Bruce J. Trock, Phillip M. Pierorazio, Thomas R. Nirschl, Daniela C. Salles, Julie E. Stein, Tamara L. Lotan, Janis M. Taube, Charles G. Drake, Mohamad E. Allaf

Summary: In this study, the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma were evaluated. The study demonstrated the safety of this approach and found that a subset of patients may have features of an immune-related pathologic response.

EUROPEAN UROLOGY ONCOLOGY (2022)

No Data Available